27 May 2022

Diaceutics PLC

("Diaceutics" or "the Company")

Issue of and changes to Share Options/PDMR Shareholdings

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces the issue of 200,000 share options over ordinary shares of £0.002 each in the Company ("Share Options") to certain directors and members of the Company's senior management team as part of their remuneration package and pursuant to the Company's Employee Share Option Plan ("ESOP"), and provides an update on the arrangements for the share options held by Philip White.

Share Options were granted as follows:

The Share Options issued to the Director and CFO, Nick Roberts, vest over three years from the point of employment start (being 18^th March 2022) and are subject to continued employment.

The Share Options issued to Julie Browne and the other employee vest in tranches over a three-year period from the point of employment start (being 14^th March 2022 and 1^st January 2022 respectively), and to Stefan McDonald from the date of his promotion to the Company's senior management team (being 1^st September 2021) and are subject to continued employment.

The exercise price of the Share Options granted is £0.002 per share which equates to the nominal value of the shares.

Following this grant, the total number of share options outstanding in the Company is 3,308,118, representing approximately 3.92% of its current issued share capital of 84,472,431.

Further to the announcement on 11 January 2022 and, as part of the orderly handover of duties Phillip White (former CFO and Director) is facilitating, the Board has agreed that all his outstanding share options would vest immediately (including those which are currently out of the money). As provided in the scheme rules, these options are require to be exercised within 90 days of vesting.

Phillip White's outstanding share options are as follows:

The above arrangements with Philip White constitute a related party transaction under the AIM Rules for Companies.  The directors, excluding Philip White who is no longer a director, consider, having consulted with the Company's nominated adviser, Stifel Nicolaus Europe Limited, that the terms of the transaction are fair and reasonable insofar as the Company's shareholders are concerned.

Enquiries:

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®. 

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.